Original Article
SABR/SBRT for oligometastatic cancer within NHS commissioning through evaluation program—a single centre experience
Abstract
Background: To describe the oligometastasis treated with stereotactic ablative body radiotherapy (SABR) at our center.
Methods: We reviewed outcome and tolerance for patients treated for oligometastatic disease with SABR from January 2015 to November 2016 at our centre. Evaluation Questionnaires completed by physicians and patients, as quality of life, pain score and toxicity were gathered before and in every follow-up appointment, as well as disease status.
Results: Fourteen patients were included. The median follow-up was 6.5 months (range, 0.69–15.41 months). The treatment was very well tolerated and all of them kept a very good quality of life.
Conclusion: SABR seems to be a safe and cost-effective treatment. Further data from randomised studies as CORE are needed to determine if the high local control rates and improved disease progression survival could translate into an overall survival benefit.
Methods: We reviewed outcome and tolerance for patients treated for oligometastatic disease with SABR from January 2015 to November 2016 at our centre. Evaluation Questionnaires completed by physicians and patients, as quality of life, pain score and toxicity were gathered before and in every follow-up appointment, as well as disease status.
Results: Fourteen patients were included. The median follow-up was 6.5 months (range, 0.69–15.41 months). The treatment was very well tolerated and all of them kept a very good quality of life.
Conclusion: SABR seems to be a safe and cost-effective treatment. Further data from randomised studies as CORE are needed to determine if the high local control rates and improved disease progression survival could translate into an overall survival benefit.
